このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Sangamo Therapeutics マネジメント
マネジメント 基準チェック /24
現在、CEO に関する十分な情報がありません。
主要情報
Sandy Macrae
最高経営責任者
US$2.4m
報酬総額
| CEO給与比率 | 29.9% |
| CEO在任期間 | 8yrs |
| CEOの所有権 | 0.2% |
| 経営陣の平均在職期間 | 2yrs |
| 取締役会の平均在任期間 | 4.6yrs |
経営陣の近況
Recent updates
Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price Drop
Jun 19
We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package
May 29This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This Year
May 14Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding
Mar 23Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%
Mar 16We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate
Mar 09Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Find Their Feet
Feb 02Here's Why We're A Bit Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation
Dec 04Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Worth US$0.9 Based On Its Intrinsic Value?
Sep 11Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates
Aug 15Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Low P/S
Aug 08Analysts Are More Bearish On Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Than They Used To Be
May 30Analysts Just Published A Bright New Outlook For Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO)
May 13Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky
Apr 11We Think Sangamo Therapeutics (NASDAQ:SGMO) Needs To Drive Business Growth Carefully
Dec 20Pfizer, Sangamo reopen recruitment for late-stage trial of hemophilia A gene therapy
Sep 22Here's Why We're Watching Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation
Sep 18Sangamo Therapeutics: Strong Fabry Data Puts Them In The Lead
Aug 31Sangamo Therapeutics: Cheap, But Justifiably So
Aug 09Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates
May 08Will Sangamo Therapeutics (NASDAQ:SGMO) Spend Its Cash Wisely?
Apr 11Sangamo Therapeutics: Lost In Transition From Lab To Clinic
Feb 24Is Sangamo Therapeutics (NASDAQ:SGMO) In A Good Position To Deliver On Growth Plans?
Jan 10Sangamo Therapeutics: Remaining Bullish Ahead ASH Data In December
Dec 03We're Interested To See How Sangamo Therapeutics (NASDAQ:SGMO) Uses Its Cash Hoard To Grow
Sep 22Sangamo Therapeutics: Finding An Opportunity To Reload
Aug 21Sangamo's Hemophilia A Treatment: An Assessment
May 31We Think Some Shareholders May Hesitate To Increase Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation
May 19Sangamo Therapeutics Q1 2021 Earnings Preview
May 03CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$328m |
| Dec 31 2023 | US$2m | US$716k | -US$258m |
| Sep 30 2023 | n/a | n/a | -US$250m |
| Jun 30 2023 | n/a | n/a | -US$199m |
| Mar 31 2023 | n/a | n/a | -US$127m |
| Dec 31 2022 | US$5m | US$709k | -US$192m |
| Sep 30 2022 | n/a | n/a | -US$178m |
| Jun 30 2022 | n/a | n/a | -US$172m |
| Mar 31 2022 | n/a | n/a | -US$176m |
| Dec 31 2021 | US$5m | US$689k | -US$178m |
| Sep 30 2021 | n/a | n/a | -US$181m |
| Jun 30 2021 | n/a | n/a | -US$135m |
| Mar 31 2021 | n/a | n/a | -US$124m |
| Dec 31 2020 | US$4m | US$682k | -US$121m |
| Sep 30 2020 | n/a | n/a | -US$76m |
| Jun 30 2020 | n/a | n/a | -US$102m |
| Mar 31 2020 | n/a | n/a | -US$96m |
| Dec 31 2019 | US$4m | US$662k | -US$95m |
| Sep 30 2019 | n/a | n/a | -US$118m |
| Jun 30 2019 | n/a | n/a | -US$104m |
| Mar 31 2019 | n/a | n/a | -US$90m |
| Dec 31 2018 | US$4m | US$636k | -US$68m |
| Sep 30 2018 | n/a | n/a | -US$63m |
| Jun 30 2018 | n/a | n/a | -US$62m |
| Mar 31 2018 | n/a | n/a | -US$58m |
| Dec 31 2017 | US$2m | US$612k | -US$55m |
報酬と市場: Sandyの 総報酬 ($USD 2.39M ) は、 US市場 ($USD 673.68K ) の同規模の企業の平均を上回っています。
報酬と収益: Sandyの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Sandy Macrae (61 yo)
8yrs
在職期間
US$2,392,272
報酬
Dr. Alexander D. Macrae, also known as Sandy, M.B., Ch B, Ph D., MRCP, serves as an Independent Non-Executive Director of 4D pharma plc since August 27, 2019.Dr. Macrae has been the Chief Executive Office...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, President & Director | 8yrs | US$2.39m | 0.18% $ 158.0k | |
| Senior VP | 5yrs | US$1.06m | 0.034% $ 29.6k | |
| Senior VP & Chief Development Officer | 5.4yrs | US$1.03m | 0.040% $ 34.8k | |
| Head of Research | less than a year | データなし | 0.013% $ 11.3k | |
| Head of Technology | less than a year | データなし | データなし | |
| Head of Corporate Communications & Investor Relations Officer | no data | データなし | データなし | |
| Senior VP | 2.8yrs | データなし | 0.038% $ 33.5k | |
| Head of Technical Operations | 1.1yrs | データなし | データなし | |
| Head of Business Development & Alliance Management | less than a year | データなし | データなし | |
| Scientist II - Discovery & Translational Research | no data | データなし | データなし | |
| Vice President of Investor Relations & Corporate Communications | no data | データなし | データなし |
2.0yrs
平均在職期間
55yo
平均年齢
経験豊富な経営陣: SGMOの経営陣は 経験豊富 とはみなされません ( 2年の平均在職年数)。これは新しいチームを示唆しています。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, President & Director | 8yrs | US$2.39m | 0.18% $ 158.0k | |
| Independent Chairwoman of the Board | 10yrs | US$99.28k | 0.030% $ 26.5k | |
| Independent Director | 8yrs | US$80.53k | 0.024% $ 21.0k | |
| Member of Scientific Advisory Board | 4.6yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 4.6yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 4.6yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 4.6yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 4.6yrs | データなし | データなし | |
| Independent Director | 6yrs | US$76.78k | 0.025% $ 22.1k | |
| Member of Scientific Advisory Board | 4.6yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 4.6yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 4.6yrs | データなし | データなし |
4.6yrs
平均在職期間
66.5yo
平均年齢
経験豊富なボード: SGMOの 取締役会 は 経験豊富 であると考えられます ( 4.6年の平均在任期間)。